Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866703 | 0.93 | PPARG (0.71) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL9372697 | 0.91 | PPARG (0.68) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL9570559 | 0.90 | MAPT (0.83) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL6202350 | 0.86 | FFAR1 (0.73) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL9375186 | 0.85 | PPARG (0.61) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL1299855 | 0.85 | FFAR1 (0.80) | PPARGMAPTKMT2AFFAR1PPARA | |
| SCHEMBL290413 | 0.85 | MAPT (0.75) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL1072226 | 0.85 | FFAR1 (0.77) | PPARGMAPTKMT2AFFAR1PPARA | |
| SCHEMBL9372807 | 0.84 | PPARG (0.60) | PPARGMAPTMAOBCA2KMT2A | |
| SCHEMBL12515224 | 0.84 | FFAR1 (0.69) | PPARGFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146805-A | Production method for thiazolidinedione compound and its production intermediate | SANKYO CO (JP) | 2008-03-19 | — | — | CN | claimed |
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | ARACHNOVA THERAPEUTICS LTD. (JE) | 2004-08-05 | — | — | US | claimed |
| EP-1385516-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | Arachnova Therapeutics Ltd. (GB) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087576-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | ARACHNOVA THERAPEUTICS LTD. (GB) | 2002-11-07 | — | — | WO | claimed |
| JP-11071358-A | — | — | None | — | — | JP | disclosed |
| JP-11049763-A | — | — | None | — | — | JP | disclosed |
| US-11478471-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | STRONGBRIDGE DUBLIN LIMITED (IE) | 2022-10-25 | — | — | US | disclosed |
| US-20210299122-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS | XERIS PHARMACEUTICALS, INC. | 2021-09-30 | — | — | US | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10835530-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | STRONGBRIDGE DUBLIN LIMITED (IE) | 2020-11-17 | — | — | US | disclosed |
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-5061717-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0389699-A1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4883879-A | CHEMICAL INTERMEDIATES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| WO-1989008652-A1 | THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008650-A1 | THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4822786-A | Cephalosporin compounds, and antibacterial agents | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0294995-A1 | Oxazolidin-2-one derivatives as hypoglycemic agents | PFIZER INC. (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | PPARA, PPARD, PPARG | PPARG 3/4885MAPT 4179/4885MAOB 4139/4885 |
| US-20210299122-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS | CYP11B2, HSD3B2, HSD3B1 | PPARG 258/4885MAPT 916/4885MAOB 3688/4885 |
| US-10835530-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | CYP11B2, HSD3B2, HSD3B1 | PPARG 258/4885MAPT 916/4885MAOB 3688/4885 |
| US-11478471-B2 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | CYP11B2, HSD3B2, HSD3B1 | PPARG 271/4885MAPT 912/4885MAOB 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.